Cognition Therapeutics Inc. (CGTX:NASDAQ), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative disorders, is advancing an investigational oral drug designed to protect connections between brain cells from damage associated with Alzheimer's disease. Its lead candidate, zervimesine (CT1812), targets the sigma-2 receptor complex to prevent toxic protein clusters called amyloid-beta oligomers from binding to neuronal synapses. The company is evaluating the treatment in its ongoing Phase 2 START study in early Alzheimer's disease, with topline results expected in the second half of 2027.
Key Takeaways
- Zervimesine is designed to prevent toxic amyloid-beta oligomers from attaching to brain-cell connections, potentially helping preserve synaptic function.
- The Phase 2 START study enrolled 545 participants with mild cognitive impairment or early Alzheimer's disease; topline results are expected in H2 2027.
- A separate Phase 3 program in dementia with Lewy body psychosis is targeted to begin in mid-2027.
- A CTAD poster scheduled for November 19 will describe how blood-based p-tau217 testing helped streamline participant screening in START.
- Cognition reported approximately US$31.5 million in cash, cash equivalents, and restricted cash at the end of Q3 2026, plus US$18.2 million in remaining obligated grant funding.
CTAD Poster on Biomarker Screening
The poster, titled "Plasma p-tau217 In Early Alzheimer's Disease Trial Screening: Insights from START," will be presented on November 19, 2026, in Boston. It draws from the START study (COG0203, NCT05531656), which evaluates once-daily oral zervimesine (CT1812) or placebo in 545 individuals with mild cognitive impairment or early Alzheimer's disease. Enrollment was completed in Q4 2025, with top-line results expected after the last participants have completed 18 months of treatment in H2 2027.
Analysis showed that measuring plasma p-tau217 at initial screening helped exclude ineligible participants before confirmatory amyloid PET scans, potentially reducing costs, resource use, and burden on participants and sites.
"PET scans can assess the presence of amyloid in the brain consistent with Alzheimer's disease," explained lead author Marina Ritchie, Ph.D., of USC. "As a less invasive and more scalable screening tool, early incorporation of plasma biomarkers into the trial screening process may help identify individuals unlikely to meet biomarker eligibility criteria and reduce unnecessary screening visits for participants."
Cognition Therapeutics' lead candidate, zervimesine (CT1812), is an oral small molecule targeting toxic protein oligomers. The company recently aligned with the FDA on key elements of a planned registrational Phase 3 trial in dementia with Lewy bodies (DLB) psychosis, targeting a mid-2027 start. Phase 2 SHIMMER results in DLB showed positive signals on safety, tolerability, and efficacy measures, including neuropsychiatric symptoms.
In Q3 2026, Cognition reported a narrowed net loss of US$4.1 million and cash, cash equivalents, and restricted cash of approximately US$31.5 million as of September 30, 2026, plus US$18.2 million in remaining obligated NIA grant funds. Management expects that its cash is sufficient to fund operations and capital expenditures into Q4 2027.
Alzheimer's Needs Further Treatment Development
Alzheimer's disease is a progressive neurodegenerative disorder and the most common cause of dementia, accounting for an estimated 60% to 80% of dementia cases, according to the Alzheimer's Association's 2026 Facts and Figures report. The disease gradually damages brain cells, affecting memory, thinking, and communication, and eventually a person's ability to perform everyday activities. Although age is the greatest known risk factor, Alzheimer's is not considered a normal part of aging, and younger-onset cases can also occur.
The prevalence of Alzheimer's disease continues to increase alongside the aging population. According to the Alzheimer's Association's 2026 report, an estimated 7.4 million Americans aged 65 and older are living with clinical Alzheimer's dementia in 2026, representing approximately one in nine people in that age group. Without medical breakthroughs capable of preventing or curing the disease, that figure could reach 13.8 million by 2060. The association also estimates that U.S. health, long-term care, and hospice costs for people age 65 and older with dementia will reach US$409 billion in 2026, highlighting the growing economic burden on healthcare systems, families, and caregivers.
The treatment landscape has also begun to shift from managing symptoms toward targeting underlying disease processes. Alzheimer's is associated with the accumulation of beta-amyloid plaques and tau protein tangles in the brain, both of which are major areas of pharmaceutical research. Two FDA-approved disease-modifying treatments are Leqembi (lecanemab), an amyloid-beta-directed antibody approved by Eisai, and Kisunla (donanemab), developed by Eli Lilly. Both treatments are intended for patients in the early symptomatic stages of Alzheimer's disease and have demonstrated an ability to slow clinical decline in clinical trials, rather than reverse existing cognitive damage. The FDA's respective Leqembi approval and treatment information and Kisunla approval announcement provide additional details about their indications and clinical results.
Raghuram Selvaraju of H.C. Wainwright & Co. also maintained a "Buy" rating, with a 12-month price target of US$3.
Treatment delivery is also evolving. In July 2026, the FDA approved a new starting dosage regimen for Leqembi's subcutaneous formulation, allowing eligible patients to begin treatment through at-home administration by themselves or a caregiver. Previously, treatment initiation required intravenous administration. The change represents an additional option for patients and caregivers, although treatment still requires medical supervision and carries potential risks, including amyloid-related imaging abnormalities (ARIA).
Alongside drug development, advances in diagnostic testing are creating additional opportunities for the sector. Historically, identifying Alzheimer's-related pathology has relied on cognitive assessments, cerebrospinal fluid testing, and brain imaging, including amyloid PET scans. Blood-based biomarkers are emerging as a less invasive diagnostic tool that could help identify patients with Alzheimer's-related biological changes. In May 2025, the FDA cleared Fujirebio's Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, the first blood test authorized to aid in diagnosing Alzheimer's disease. The test is intended for adults aged 55 and older who exhibit signs and symptoms of cognitive decline. It is not intended to serve as a standalone diagnostic or general screening tool, and results must be interpreted alongside other clinical information.
Despite these advances, Alzheimer's remains an area of substantial unmet medical need. Existing disease-modifying treatments are intended for specific stages of the disease, require careful patient selection and monitoring, and do not constitute a cure. Researchers continue investigating alternative mechanisms, earlier interventions, and treatments for additional symptoms. The development of more accessible diagnostic tools, improvements in treatment delivery, and continued clinical research are among the areas investors may monitor as pharmaceutical and biotechnology companies pursue opportunities in the Alzheimer's market.
Zervimesine is an oral small-molecule drug designed to protect neuronal synapses, the connections that allow brain cells to communicate. Cognition Therapeutics is targeting the sigma-2 receptor complex, a structure found at neuronal synapses that the company believes plays a role in the harmful effects of toxic protein clusters. In Alzheimer's disease, small clusters of amyloid-beta proteins, known as oligomers, can attach to synapses and interfere with their normal function.
By binding to the sigma-2 receptor complex, zervimesine is designed to change the interaction between these oligomers and their binding sites, helping displace the toxic proteins from synapses and prevent them from attaching again. Cognition believes this approach could help preserve synaptic connections and function, potentially slowing cognitive decline. The proposed mechanism is supported by preclinical research and biomarker findings, but its ability to produce meaningful clinical benefits in Alzheimer's patients remains under investigation.
Analysts Offer 'Buy' Ratings
In a November 5, 2026, research report, Fozia Ahmed of Brookline Capital Markets maintained a "Buy" rating for Cognition Therapeutics with a US$4 price target. Ahmed pointed to the FDA's agreement with the company on key parts of its planned Phase 3 trial of zervimesine for DLB. Brookline's price target is based on the potential use of zervimesine in mild cognitive impairment, mild Alzheimer's disease, and DLB, as well as the company's cash position. Ahmed also noted that the company would need additional funding to advance its programs.
On November 9, 2026, Raghuram Selvaraju of H.C. Wainwright & Co. also maintained a "Buy" rating, with a 12-month price target of US$3. Selvaraju viewed the FDA's agreement on the planned DLB trial as an important step forward. He highlighted the study's planned focus on hallucinations and delusions, along with its assessment of patients' ability to manage daily activities. The trial is expected to begin enrolling patients in mid-2027. Its US$3 price target is based on an estimated company value of approximately US$290 million, calculated using the potential value of zervimesine across its DLB and Alzheimer's programs.
Ownership and Share Structure1
Institutions hold about 23.76% of Cognition Therapeutics, while Management and insiders own approximately 10.23%, with retail investors accounting for the balance.
The largest disclosed holders include Aaron G.L. Fletcher (6.40%), BIOS Capital Management, LP (6.31%), Davenport & Co LLC (4.48%), Vanguard Capital Management LLC (3.62%), and Lisa Ricciardi (1.80%).
The company has roughly 95.06 million shares outstanding and a market capitalization of about $60 million.
No verified insider open-market buys or sells were found for the last six months.
One series of warrants remains outstanding. No historical share restructures were found.
Common Questions from Investors
What does the CTAD poster reveal about screening in the START study?
The poster highlights how early plasma p-tau217 testing excluded ineligible participants before PET scans, potentially streamlining screening and reducing burden, as detailed in the November 17, 2026, announcement.
When are topline results from the START study expected?
Topline results from the Phase 2 START study in mild cognitive impairment and early Alzheimer's disease are expected in the second half of 2027, after the final participants complete 18 months of treatment.
What is the status of the DLB program?
Cognition has FDA alignment on key elements of a planned Phase 3 registrational trial in DLB psychosis, with a targeted start in mid-2027, building on positive Phase 2 SHIMMER data.
How is the company funded for ongoing trials?
The START study is supported by NIA grants. Cognition estimates that its cash is sufficient to fund operations and capital expenditures into Q4 2027.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
Ownership percentages, named holders, share count, market capitalization, and the 52-week range for Cognition Therapeutics were compiled from company public filings and investor materials, exchange notices, insider-trade reports (SEDI / equivalent), and third-party data providers. Figures are as of 2026-11-18 unless a source was dated earlier. Pie slices are normalized to 100% of basic shares outstanding; retail is the residual after disclosed institutions, management, insiders, and strategic holders. Warrant terms are current outstanding series only. Restructures are historical consolidations, splits, and symbol or name changes. Insider buying and selling covers open-market trades from the prior six months through 2026-11-18 and excludes option exercises. These are public-source estimates and can differ from a later official register.


















































